NY A02156

Expands Medicaid coverage for ovulation enhancing drug treatment to include both oral and injectable medications, whereas previous law did not specify the drug delivery method

Changes terminology in the law from "women" to "patients" to use gender-neutral language for those receiving fertility treatment

Covered services include ovulation enhancing drug treatment, office visits, hysterosalpingogram services, pelvic ultrasounds, and blood testing necessary to monitor treatment

Provides that if 90% federal financial participation is unavailable, state funds would instead support a grant program to accomplish the same purpose

Takes effect 90 days after becoming law